Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Total Valuation
Evaxion Biotech has a market cap or net worth of $29.86M. The enterprise value is $6.88M.
Market Cap$29.86M
Enterprise Value$6.88M
Share Statistics
Evaxion Biotech has 6,316,572 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,316,572
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Evaxion Biotech’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -33.55%.
Return on Equity (ROE)-0.45
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-33.55%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee164.15K
Profits Per Employee-168.06K
Employee Count46
Asset Turnover0.27
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Evaxion Biotech is ―. Evaxion Biotech’s PEG ratio is 0.05.
PE Ratio―
PS Ratio4.05
PB Ratio1.79
Price to Fair Value1.79
Price to FCF-4.59
Price to Operating Cash Flow-3.45
PEG Ratio0.05
Income Statement
In the last 12 months, Evaxion Biotech had revenue of 7.55M and earned -7.73M in profits. Earnings per share was -1.21.
Revenue7.55M
Gross Profit0.00
Operating Income-9.26M
Pretax Income-8.64M
Net Income-7.73M
EBITDA-8.65M
Earnings Per Share (EPS)-1.21
Cash Flow
In the last 12 months, operating cash flow was -6.65M and capital expenditures -11.03K, giving a free cash flow of -6.66M billion.
Operating Cash Flow-6.65M
Free Cash Flow-6.66M
Free Cash Flow per Share-1.05
Dividends & Yields
Evaxion Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change87.43%
50-Day Moving Average3.89
200-Day Moving Average4.01
Relative Strength Index (RSI)52.92
Average Volume (3m)46.59K
Important Dates
Evaxion Biotech upcoming earnings date is Jun 2, 2026, Before Open (Not Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateJun 2, 2026
Ex-Dividend Date―
Financial Position
Evaxion Biotech as a current ratio of 5.85, with Debt / Equity ratio of 44.04%
Current Ratio5.85
Quick Ratio5.85
Debt to Market Cap0.19
Net Debt to EBITDA1.82
Interest Coverage Ratio-10.54
Taxes
In the past 12 months, Evaxion Biotech has paid -910.78K in taxes.
Income Tax-910.78K
Effective Tax Rate0.11
Enterprise Valuation
Evaxion Biotech EV to EBITDA ratio is -1.72, with an EV/FCF ratio of -2.23.
EV to Sales1.96
EV to EBITDA-1.72
EV to Free Cash Flow-2.23
EV to Operating Cash Flow-2.23
Balance Sheet
Evaxion Biotech has $23.23M in cash and marketable securities with $7.50M in debt, giving a net cash position of $15.73M billion.
Cash & Marketable Securities$23.23M
Total Debt$7.50M
Net Cash$15.73M
Net Cash Per Share$2.49
Tangible Book Value Per Share$2.66
Margins
Gross margin is 0.00%, with operating margin of -122.66%, and net profit margin of -102.38%.
Gross Margin0.00%
Operating Margin-122.66%
Pretax Margin-114.44%
Net Profit Margin-102.38%
EBITDA Margin-114.49%
EBIT Margin-122.66%
Analyst Forecast
The average price target for Evaxion Biotech is $11.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.25
Price Target Upside214.25% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast4455.07%
EPS Growth Forecast77.31%